SIGA Completes Clinical Studies for IV Formulation of TPOXX®, NDA to be Submitted in 2020   

    NEXT STORY
    Spero Therapeutics Announces Positive Recommendation to Continue Phase 3 Clinical Trial of SPR994 as Planned Following Independent Review Committee Analysis of SPR994 Treated Patients in Lead-in Cohort of Trial
    PREV STORY
    ADMA Biologics Announces Poster Presentation at IDWeek 2019
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Medtronic Announces Preliminary PRODIGY Results: a Global Study to Identify Patients at High Risk for Opioid-Induced Respiratory Compromise

    author_avatar
    NASDAQ Market News

    Probiotic Ingredients Market To Reach USD 497.0 Million By 2027 | Growing Awareness and Demand for ‘Immunity Boosting’ Food-Products are Expected to Drive Market Growth, says Reports and Data

    author_avatar
    NASDAQ Market News

    XORTX Launches XRx-101 Following the Filing of a Provisional Patent to Potentially Treat Respiratory and Kidney Disease Injury Due to Coronavirus Infection

    author_avatar
    NASDAQ Market News